Filing Flows › Enanta Pharmaceuticals (ENTA) › Q3 FY26
Enanta Pharmaceuticals (ENTA) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Aug 12, 2026
Enanta Pharmaceuticals (ENTA) reported revenue of $14.4M for the third quarter fiscal 2026 (Q3 FY26), -22% from a year earlier and -16% from the quarter before. Operating margin was -120.0%, net loss $19.5M (135.8% of revenue).
Enanta Pharmaceuticals, Q3 FY26: revenue $14.4M (-22% year over year), operating margin -120.0%, net loss $19.5M, operating cash flow −$10.0M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.4M | -16% | -22% |
| Operating profit | −$17.2M | — | — |
| Net earnings | −$19.5M | — | — |
| Operating cash flow | −$10.0M | — | -157% |
What changed
Revenue was $14.4M in Q3 FY26, down 22% year over year and down 16% from the previous quarter.
Operating costs exceeded revenue by $17.2M, an operating margin of -120.0%. Total costs fell 15% while revenue fell 22%. The quarter ended with a net loss of $19.5M, wider than the previous quarter's $13.1M loss.
Operating cash flow was −$10.0M. Non-cash charges added back $1.2M of depreciation and amortization and $3.7M of share-based compensation. Working capital and other items added $4.7M. Capital expenditures of $7K exceeded it, leaving free cash flow of −$10.0M.
Questions
What was Enanta Pharmaceuticals' revenue in the third quarter fiscal 2026?
Enanta Pharmaceuticals (ENTA) reported revenue of $14.4M for the third quarter fiscal 2026 (Q3 FY26), -22% from a year earlier and -16% from the quarter before.
Was Enanta Pharmaceuticals profitable in the third quarter fiscal 2026?
Operating loss was $17.2M (-120.0% of revenue) and net loss $19.5M.